Clinical Trials Browser

Interventional × Disease Progression × Other hematologic neoplasm × Clear all

Leukemia, Plasma Cell, Disease Progression

NCT03154190 2025-01-24

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicMyeloidOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Melanoma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Disease Progression, Triple Negative Breast Neoplasms

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Phase 1 Active not recruiting

24 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

11 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT04029038 2023-08-21

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Disease Progression

NCT04149821 2023-06-15

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Phase 2 Terminated

1 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

Clinical Trials

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy